UPDATE: Goldman Sachs Upgrades Hill-Rom Holdings to Buy Hospita Bed Market Rebound
Goldman Sachs raised its rating on Hill-Rom Holdings (NYSE: HRC) from Neutral to Buy and increased its price target from $30 to $39.
Goldman Sachs commented, "Our Buy rating is based on the following: (1) a stabilization and potential improvement in the company's core bed business, notably in the US, which should help drive a positive inflection point on the top line in the near to intermediate term; (2) International expansion helping to support longer term results; and (3) an improved outlook on the company's M&A strategy."
Hill-Rom Holdings closed at $28.07 on Monday.
Latest Ratings for HRC
|Feb 2017||Barclays||Initiates Coverage On||Overweight|
|Jan 2017||Stifel Nicolaus||Initiates Coverage On||Buy|
|Jun 2016||Morgan Stanley||Upgrades||Equal-Weight||Overweight|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.